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Summary
Context Partial lipodystrophy (PL) is associated with metabolic
co-morbidities but may go undiagnosed as the disease spectrum
is not fully described.
Objective The objective of the study was to define disease spec-
trum in PL using genetic, clinical (historical, morphometric)
and laboratory characteristics.
Design Cross-sectional evaluation.
Participants Twenty-three patients (22 with familial, one
acquired, 783% female, aged 12–64 years) with PL and non-
alcoholic fatty liver disease (NAFLD).
Measurements Genetic, clinical and laboratory characteristics,
body composition indices, liver fat content by magnetic reso-
nance imaging (MRI), histopathological and immunofluores-
cence examinations of liver biopsies.
Results Seven patients displayed heterozygous pathogenic vari-
ants in LMNA. Two related patients had a heterozygous, likely
pathogenic novel variant of POLD1 (NM0026913: c.3199 G>A;
p.E1067K). Most patients had high ratios (>15) of percentage
fat trunk to percentage fat legs (FMR) when compared to refer-
ence normals. Liver fat quantified using MR Dixon method was
high (113  63%) and correlated positively with haemoglobin
A1c and triglycerides while leg fat by dual-energy X-ray absorp-
tiometry (DEXA) correlated negatively with triglycerides.
In addition to known metabolic comorbidities; chronic pain
(783%), hypertension (565%) and mood disorders (522%)
were highly prevalent. Mean NAFLD Activity Score (NAS) was
5  1 and 783% had fibrosis. LMNA-immunofluorescence
staining from select patients (including one with the novel
POLD1 variant) showed a high degree of nuclear atypia and
disorganization.
Conclusions Partial lipodystrophy is a complex multi-system
disorder. Metabolic parameters correlate negatively with extrem-
ity fat and positively with liver fat. DEXA-based FMR may prove
useful as a diagnostic tool. Nuclear disorganization and atypia
may be a common biomarker even in the absence of pathogenic
variants in LMNA.
(Received 3 November 2016; returned for revision 18 January
2017; finally revised 18 January 2017; accepted 10 February 2017)
Introduction
Partial lipodystrophy (PL) is a cluster of rare heterogeneous
diseases characterized by selective loss of adipose tissue, which
places patients at risk of common conditions typically associated
with metabolic syndrome.1–3 Commonly associated features are
insulin resistance and diabetes, hypertriglyceridaemia and non-
alcoholic fatty liver disease (NAFLD).4 PL may be acquired or
inherited and pathogenic variants in multiple genes have been
identified as causative for inherited PL including LMNA,
PPARG, PLIN1, AKT2, CIDEC2 and more recently LIPE5 and
ADRA2A.6
One obstacle in development of novel treatment strategies for
these disorders has been the lack of documentation of the differ-
entiating features of these syndromes from more common forms
of truncal obesity with metabolic syndrome and Type 2 diabetes.
This was noted during the Advisory Meeting of the FDA for
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approval of Metreleptin for the treatment of lipodystrophy
syndromes (http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic
DrugsAdvisoryCommittee/UCM379648.pdf). Another problem is
the lack of objective description of natural history and disease
burden. Stated differently, are patients with PL facing different
clinical problems, comorbidity risk and mortality compared to
patients with more common metabolic disorders such as Type 2
diabetes and truncal obesity? If the answers to these questions
are yes, then the pursuit of specific treatments for these disor-
ders will be of high value despite the small number of patients
afflicted with PL.
Our study is one of the first in the field to specifically describe
the baseline drug-na€ıve state of patients participating in a drug
trial. Accumulation of data such as these presented here may
allow more precise definition of the disease state, possibly help-
ing the development of specific diagnostic criteria or disease
severity scores. We also hope to increase recognition of similar
patients by providing extensive clinical data to endocrinologists.
Methods
We have been recruiting patients with PL for an open-label
study conducted at the University of Michigan funded by
NIDDK (approved by University of Michigan IRBMED) to eval-
uate the molecular effects of an investigational drug on treating
liver disease associated with PL (ClinicalTrials.gov identifier:
NCT01679197, HUM00058708). Here, we describe baseline char-
acteristics of 23 patients who completed screening and study ini-
tiation procedures but have not received any investigational
drug. Diagnosis of PL was based on physician assessment with
evidence of selective loss of body fat.3 Patients with both inher-
ited and acquired forms of PL were included, excluding lipodys-
trophy associated with human immunodeficiency virus (HIV).
Patients entering this study had a liver ultrasound showing the
presence of fatty liver disease or prior biopsy showing evidence
of non-alcoholic steatohepatitis (NASH), no evidence of other
forms of liver disease and alcohol consumption of <40 g/week.
After informed consent was obtained from all patients or
guardians, physical examinations were performed and previous
medical records were examined to verify historical details. Blood
samples after overnight fast were analyzed for estimating leptin
levels using a commercial enzyme linked immunosorbent assay
(ELISA) kit (EMDMilipore, Billerica, MA,USA). Haemoglobin
A1c, fasting lipids and hepatic function tests were determined in
the Clinical Pathology Laboratory of University of Michigan
using auto-analyzer equipment.
Clinical and research resources were used to determine the
molecular basis of disease in patients (described in
Appendix S1). Body composition was evaluated using anthropo-
metric measurements, including skin thickness and waist and
hip circumferences using standardized techniques. Fat and lean
body mass were estimated using dual X-ray absorptiometry
(DEXA; GE Lunar Prodigy, model PA +41744, Madison, WI,
USA).7 Ratio of percent fat mass of the trunk to percent fat
mass of the legs (FMR) was calculated.
For determination of hepatic fat content, magnetic resonance
(MR) imaging using quantitative multi-echo Dixon method and
multi-echo MR spectroscopy have been employed (method
described in Appendix S1 and Figure S1). Transcutaneous liver
biopsies were performed and total NASH scores were calculated
from histopathological examination using the simplified clinical
criteria as presented in Table S1, which is a modified and clini-
cally applied version of NIH NASH Clinical Network Criteria.8
NASH score equals the sum of scores for steatosis (range, 0–3),
lobular inflammation (range, 0–3), hepatocellular ballooning
(range, 0–2) and fibrosis (range, 0–4). NAFLD activity score
(NAS) includes these parameters, but without fibrosis. In addi-
tion, selective liver biopsy specimens were processed for lamin
A/C immunofluorescence staining and then scored in a blinded
fashion (methods described under Appendix S1).
Statistical analyses were performed using GRAPHPAD Prism ver-
sion 605 (LaJolla, CA, USA) and SAS version 92 (Cary, NC,
USA). Correlations were investigated by calculating Pearson’s
correlation coefficient. Two-tailed P-value was calculated, and
P < 005 was considered statistically significant. For quantitation
of lamin immunofluorescence data, statistical significance was
determined via one-way ANOVA followed by Tukey’s post-hoc test
at a threshold of P < 005.
Results
Patient characteristics and genetic evaluation
Twenty-three patients with PL were enrolled who were 12–
64 years old (median age, 43 years): 18 female and five male.
The majority, 20 patients were Caucasian, two Hispanic and one
African-American. Summary characteristics are shown in
Table 1, and detailed clinical data can be found in Tables S2–S5.
Of known genes, LMNA variants were quite common, identified
in seven patients. Of these seven patients, five had a heterozy-
gous pathogenic variant at position 482, the hot spot. Four of
these patients harboured R482Q pathogenic variant (two sisters,
patients 13 and 20, and two unrelated patients, 17 and 18). One
patient (patient 21) harboured the previously reported R482W
pathogenic variant and was also diagnosed with muscular dys-
trophy.9 Patient 10 also harboured a previously reported R60G
pathogenic variant10 and had a history of dilated non-ischaemic
cardiomyopathy requiring heart transplant at age 25. Patient 22
was heterozygous for LMNA R349W and had unique clinical
features including loss of fat from the face, hands and feet, a
large dorsocervical fat pad, proteinuria, cardiomyopathy
(believed to be both primary and ischaemic), infertility, hyper-
androgenism and alopecia (Fig. 1, Tables S2-S5). Another inter-
esting laboratory abnormality in patient 22 is low alkaline
phosphatase level, typically associated with progeria.11,12 There
have been two other published instances of this mutation, one
in a male patient with similar fat distribution, but without the
exaggerated dorsocervical fat pad, diabetes, or other features
described here.13 In addition, a large kindred with focal segmen-
tal glomerulosclerosis and proteinuria in association with PL has
been reported.14
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Two related patients (mother and daughter, 6 and 7) had a
variant in Exon 26 of POLD1 (NM0026913: c.3199G>A;
p.E1067K, Fig. 1, Figures S2 and S3 and Tables S2–S5) which we
classified as a variant of unknown significance, which is most
likely pathogenic. Two patients (four and nine) did not harbour
mutations in the known 15 LD genes (see Appendix S1) interro-
gated with whole exome sequencing (WES). WES for the other
11 patients is currently in progress but they did not harbour
LMNA p.R482 variants using specific sequencing for this locus
as described in Appendix S1.
Body composition
All but one patient had a pattern of fat loss consistent with that
seen in familial partial lipodystrophy (FPLD) in which there is
fat atrophy of the upper and lower extremities as well as the pel-
vis, with relative fat sparing or accumulation in the neck, trunk
and abdomen. One patient had acquired partial lipodystrophy
with fat atrophy in the upper body and preservation of fat in
the legs. FMR in this patient was 084, while in the other 22
patients, FMR was higher, 178  053. Using the Third
National Health and Nutrition Examination Survey (NHANES
III) reference data15 and the conversion to Lunar equipment
previously reported,16 patients were matched for gender, race
and age and the majority had FMR well above 95% confidence
interval of reference median values (Fig. 1). We also compared
the FMR obtained from our adult female patients with a group
of normal and overweight women with a BMI of 20–30 kg/m2
as well as a group of female diabetic patients with truncal obe-
sity and fatty liver disease (Figure S4) who were age-matched. A
cut-off value of 15 would be well above the normal for adult
female populations from NHANESIII as well as our two com-
parator groups with a sensitivity of 867% and specificity of
968%. There were distinctive patients with substantially higher
values, most notably patient 22.
Leg fat mass was negatively correlated with log-transformed
triglycerides (P = 00498, Fig. 2). No correlation was found
between leg fat mass and haemoglobin A1c (R2 = 006, Fig. 2),
or between leg fat mass and liver fat (R2 = 001). Mid-thigh skin
fold thickness (mean: 121  77; range, 4–29 mm) was low
compared to age-, gender- and race-matched data from
NHANES data17 (mean: 263  72; range, 123–324 mm).
Leptin levels (mean: 223  166, range 48–671 ng/ml) were
variable and in general higher than noted in studies that
enrolled only patients with leptin deficiency at the NIDDK,18
but similar to one of our previously published series.19 Leptin
levels correlated with total fat mass (P = 00071) and trunk fat
(P = 00044; Figure S5) and did not correlate with HbA1c
(R2 = 000) or triglyceride levels (R2 = 008).
Comorbidities
Prevalence of comorbidities and medications used are shown in
Fig. 3. All patients had either diabetes (826%) or pre-diabetes
(174%) with variable degree of control. Mean  SD haemoglo-
bin A1c was 86  19%. One patient (patient 14) had Type 1
diabetes with undetectable C-peptide and another patient (pa-
tient 15) had positive anti-GAD antibody at baseline. Nearly half
(11 patients) had very poor control with haemoglobin A1c
above 9%. Nineteen patients (826%) used a glucose lowering
agent. Ten patients (435%) used combination therapy with two
or more agents. Insulin was used by 12 patients (522%) and 9
of these patients required over 100 units/day. Six patients
(261%) used highly concentrated U-500 insulin.
Microvascular complications of diabetes were common.
Twelve patients (522%) had peripheral neuropathy. One patient
had a history of chronic inflammatory demyelinating polyneu-
ropathy (CIDP). Six patients had known diabetic retinopathy
based on patient report, although the prevalence may be higher
as we did not have dilated examination results for all patients.
Proteinuria or microalbuminuria was known in 10 patients
(435%). Two patients had kidney biopsies for clinical reasons,
one displaying membranoproliferative glomerulonephritis (pa-
tient 6, biopsied for massive proteinuria) and another (patient
22, biopsied for haematuria) displaying thin basement mem-
brane disease. One patient had severe gastroparesis.
Twenty-two of 23 patients had hypertriglyceridaemia (mean,
1058  1745 mg/dl). Six had very high triglycerides over
1000 mg/dl. Most (17 patients) used a lipid lowering agent
(Fig. 3). Recurrent pancreatitis occurred in seven of 23 patients
Table 1. Demographics and characteristics
Female/Male, n 18/5
Age (years), mean (range) 43 (12–64)
Race, n (%)
White 20 (870)
Black 1 (43)
Other 2 (87)
Lipodystrophy subtype, n (%)
Familial partial lipodystrophy 22 (957)
Acquired partial lipodystrophy 1 (43)
Mutation if known, n
LMNA 7
POLD1 2, subjects are related
Body weight (kg), mean (SD) 772 (214)
Body mass index (kg/m2), mean (SD) 273 (59)
Waist-to-hip ratio, mean (SD) 099 (008)
Skin fold thickness, anterior mid-thigh* (mm),
mean (SD), [range]
121 (77) [4–29]
%Fat trunk / %Fat legs*, mean (SD) 178 (053)
MR spectroscopy liver fat (%), mean (SD) 138 (61)
Dixon method MR liver fat (%), mean (SD) 119 (63)
Haemoglobin A1c (%), mean (SD) 86 (19)
Leptin level (ng/ml), mean (SD) 223 (166)
Fasting triglycerides (mg/dl), mean (SD) 1058 (1745)
AST (IU/l), mean (SD) 42 (28)
ALT (IU/l), mean (SD) 52 (37)
Haemoglobin (g/dl), mean (SD) 138 (13)
Platelets (K/ll), mean (SD) 265 (55)
Creatinine (mg/dl),mean (SD) 067 (022)
CK (IU/l), mean (SD) 145 (101)
MR, magnetic resonance; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; CK, creatine kinase.
*Excluding patient with acquired partial lipodystrophy.
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(304%). At least three episodes of pancreatitis occurred while
triglyceride levels were <800 mg/dl. Two patients who are sisters,
with known LMNA gene mutations, were found to have pancre-
atic cystic lesions on magnetic resonance imaging (MRI). One had
a single 03-cm cystic lesion in the pancreatic neck and the other
patient had multiple subcentimeter cystic lesions which may rep-
resent side branch intraductal mucinous neoplasms (Figure S6).
Mood disorder requiring medication was identified in 12
patients (522%). Depression was the most common psychiatric
condition, present in 10 patients (435%). Six had anxiety
(261%), one patient had bipolar disorder, and one had an
unidentified psychiatric condition for which he previously used
an antipsychotic agent.
Chronic pain was common among our patients. Eighteen
patients (783%) reported some type of painful condition
including neuropathy (522%), arthritis (478%), chronic back
pain (130%), fibromyalgia (174%) and myopathy (391% had
either suspected or confirmed myopathy). One patient had mus-
cular dystrophy.
Other noted conditions include coronary artery disease or
myocardial infarction in five patients (227%), one patient with
ischaemic cardiomyopathy and one patient with LMNA muta-
tion and non-ischaemic cardiomyopathy who required a heart
transplant. Hypertension was present in 13 patients (566%).
Seven patients (304%) had sleep apnoea. Three (13%) had
asthma or emphysema. Nine patients (391%) had polycystic
ovarian syndrome (PCOS).
Hepatic evaluation
Liver fat quantified using MR spectroscopy and also using
MR Dixon method showed fat percentage, mean  SD of
Fig 1 (a) Comparison of %fat trunk/%fat legs (fat mass ratio, FMR) in 23 patients with partial lipodystrophy, one of whom has acquired partial
lipodystrophy (patient 4) to age, gender and ethnic group matched reference values (median with 95% confidence interval) from NHANES data.15
Reference data were not available for paediatric patients (patients 7, 15, 23). (b) Picture of patient 22 who presented with a very high fat mass ratio
harbouring a possibly pathogenic variant at position 349 (R349W). Patient displayed loss of fat from face, extremities, including loss of supportive fat
from hands and feet, but with excessive fat deposition in the back displaying an exaggerated buffalo hump. Other clinical features included ischaemic
and non-ischaemic cardiac disease, PCO-S with severe hyper-androgenism and infertility, alopecia, haematuria (because of thin basement membrane
disease on kidney biopsy). Laboratory features included a high testosterone level and a very low alkaline phosphatase level typically associated with
progeroid disorders. (c, d) Pictures of patient 7 with a possibly pathogenic POLD1 variant. This patient and her mother displayed very severe insulin
resistance, preservation of subcutaneous fat around the face and neck and even in the abdominal wall. There was a paucity of fat in the extremities.
Patients also demonstrated stiffness in joints, elevated CK levels (mother displaying muscle weakness), proteinuria (massive in one leading to kidney
biopsy showing membranoproliferative glomerulonephritis). The patient and her mother did not have deafness. (e) X-ray of the narrow mandible for
patient 6 with possibly pathogenic POLD1 variant.
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138  61% and 119  63%, respectively (normal <5%).20
Liver fat was correlated with metabolic parameters. A positive
correlation was found between liver fat quantified using MR
Dixon method and haemoglobin A1c (P = 00431) as well as
log-transformed triglycerides (P = 00096) Fig. 2.
Of the 23 patients who underwent liver biopsy, 22 met
histopathological criteria for NASH. Total NASH scores of those
22 patients ranged 3–9 (mean, 6  2). NAS in patients who met
criteria for NASH ranged 3–8 (mean, 5  1). Eighteen patients
(783%) had some degree of fibrosis present with variable sever-
ity (stage 1a-4). One 12-year-old female patient (patient 15) had
stage 4 fibrosis (Fig. 4).
As LMNA mutations were common among the FPLD patients,
and mice with hepatocyte-specific LMNA deletion develop spon-
taneous steatosis with nuclear alterations and susceptibility to
diet-induced steatohepatitis (‘unpublished data’; authors: Ray-
mond Kwan, Graham Brady, Maria Brzozowski, Sujith Weera-
singhe, Hope Martin, Min-Jung Park, Ram Menon, Xin Tong,
Lei Yin, Colin Stewart, M. Bishr Omary), we investigated nuclear
envelope integrity from our liver biopsy samples. These early
studies were carried out on three patients with LMNA patho-
genic variants and one patient with a POLD1 p.E1067K variant.
Specimens from two patients with NASH (without lipodystro-
phy) were used as controls. Immunofluorescence staining of fro-
zen liver sections showed dysmorphic nuclei and lamin
disorganization in the patients with LMNA pathogenic variants
compared with NASH controls (Fig. 5). We also observed
abnormal nuclear morphology in the patient with POLD1 vari-
ant, although not to the same extent as the patients with LMNA
variants.
Discussion
The goal of our study is to provide a complete description of
the disease state in a cohort of 23 patients with PL. Lack of clear
documentation of clinical manifestations and full appreciation of
disease burden have become an obstacle in therapeutic develop-
ment for rare metabolic diseases given the significant hetero-
geneity in presentation.21 With this report, we are reintroducing
the idea of careful morphometric description using DEXA to
document the presence of PL. This approach may be adopted
widely as a clinical test following further validation. Also, we are
reporting a number of important clinical lessons such as the
presence of severe disease burden not only because of metabolic
disease but also because of neuropsychiatric symptoms, chronic
pain and multi-system involvement. It would be useful to collect
similar data from a larger number of patients to develop disease
severity scores taking into account the entire spectrum of clinical
findings.
Our genetic investigations have recapitulated the genetic
heterogeneity of PL with multiple patients having different
molecular basis for their disease. Several genes have been impli-
cated in various forms of FPLD including LMNA, PPARG,
PLIN1, AKT2 CIDEC, LIPE and ADR2A.2,5,6,22,23 However, the
molecular cause of disease remains unexplained in up to 40% of
patients. Lotta et al. recently reported enrichment of multiple
common variant genes in a cohort of patients formerly classified
as FLPD1, suggesting the possibility of polygenic inheritance.24
LMNA pathogenic variants are most commonly identified in
FPLD and also the most common in our cohort.22 As novel
findings, we have described two unique phenotypes, one of
which is associated with an uncommon LMNA variant
(R349W), characterized by specific body composition and clini-
cal features. We are able to add previously unrecognized clinical
characteristics (dorsocervical fat pad, ischaemic cardiac disease
and low alkaline phosphatase) to the description of this
genotype.13 As another novel finding, two related patients
(mother-daughter) were found to have a heterozygous variant of
uncertain significance in POLD1 that is possibly pathogenic and
associated with dysmorphic nuclei in the liver. POLD1 has been
previously implicated in lipodystrophy syndromes. An in-frame
deletion mutation in POLD1 was discovered in two patients with
Fig 2 Correlation was noted between metabolic
parameters of haemoglobin A1c and liver fat % (a).
as well as log transformed triglycerides and liver fat
% (b). Haemoglobin A1c was not significantly
correlated with leg fat mass (c). A significant
correlation was seen between log transformed
triglycerides and leg fat mass (d). Leg fat mass and
liver fat % did not correlate (data not shown).
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mandibular hypoplasia, deafness and progeroid features (MDP)
syndrome with lipodystrophy.25 Our patients did not have clini-
cal evidence for deafness or progeroid features, but had small
mandibles and fluctuating creatine kinase (CK) levels. Our find-
ings need to be complemented with further functional character-
ization of the observed variant. However, glutamine in position
1067 is highly conserved, within the second zinc module of the
zinc finger domain and projected to be pathogenic using in silico
algorithms (Figure S3).
Another area of interest for us was to determine whether
unique morphometric characteristics could be objectively used
as diagnostic criteria. Previously, the use of mid-thigh skin
thickness has been suggested as a field tool to screen FPLD,3,26
and this criterion has been adopted into the consensus state-
ment developed by AACE3 as well as the most recent multi-
society effort.27 In fact, recently, Guillin-Amarelle et al. have
described skin-fold characteristics of patients with the Koberling
varierty of PL, attributing a Koberling Index, the ratio of sub-
scapular to calf skinfolds (K€oB index), with a cut-off value of
3477 to be good predictor of this subtype of PL (sensitivity,
89%; specificity, 84%).28 However, accurate measurement of
skin thickness may be tricky in some patients in our experience
and we have observed high inter-observer variability while col-
lecting data. Body composition in our patients as analyzed using
DEXA showed a high FMR when compared to normative data
obtained from NHANES reference data,15 highlighting the loss
Fig 3 (a) Frequency of medication use for diabetes,
dyslipidemia, hypertension and mood disorders.
(b) Co-morbidity frequency among 23 patients
with partial lipodystrophy.
© 2017 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2017), 86, 698–707
Spectrum of disease in partial lipodystrophy 703
of fat in extremities seen in all of our patients who were classi-
fied as having FPLD. Others have proposed this approach previ-
ously in both female patients harbouring LMNA pathogenic
variants and in patients with HIV-associated lipodystrophy.26,29
In our hands, an FMR above 15 (obtained using GE Lunar
DEXA systems) in adult females may indicate an abnormal ratio
compared to a reference population taking multi-ethnic or age-
related variation into account. We are not able to suggest a cut-
off value for male patients or children in our cohort. Further
analysis of fat-related parameters in larger groups of lipodystro-
phy patients and comparison to patients with common meta-
bolic syndrome, and abdominal obesity may help establish
objective diagnostic criteria for PL.
We also present novel data showing that low leg fat was cor-
related with higher triglycerides in our unique population, sug-
gesting a pathogenic link between higher triglycerides and low
leg fat. Other researchers have reported a similar association
from other cohorts, and our patients possibly display the most
(a) (b)
(c)
Fig 4 (a) Frequency distribution of NASH scores
of liver biopsy specimens. (b) H&E and (c).
Trichrome staining of liver biopsy sample in
patient 15 (a 12-years-old with atypical PL)
showing hepatic injury and steatosis (b) stage 4
fibrosis (c).
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
(m) (n) (o)
Fig 5 Abnormal nuclear morphology and lamin distribution in livers from patients with LMNA mutations. Lamin A/C distribution (red) and nuclei
(blue) were visualized by immunofluorescence staining of frozen liver sections from patients with familial partial lipodystrophy (D–O). Liver biopsy
specimens from two patients with nonalcoholic steatohepatitis but no history of PL and no pathogenic variants in LMNA were used as controls;
representative images from one of these patients are shown (A–C). Dysmorphic nuclei and lamin disorganization are indicated by arrows in high
magnification images (right column). Scale bars 20 lm (left and middle column), 10 lm (right column). Right panels show quantification of abnormal
nuclear shape (upper right) and abnormal lamin distribution (lower right) in control NASH livers vs those from patients with LMNA and POLD1
variants. For each group, 3–4 randomly selected high-power fields were scored for each patient liver section (>150 nuclei per field, >700 nuclei per
patient). Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test at a threshold of P < 005. Error bars represent the
standard error of the mean.
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extreme version of this association.30,31 Further strengthening a
pathogenic role for absence of femoral fat, Van Pelt and col-
leagues have observed worsening lipemia after femoral lipec-
tomy.32 In contrast, higher fat in the liver in our patients is
associated with worse glucose control and higher triglycerides
(shown for the first time in a PL cohort), similar to studies in
patients with Type 2 diabetes.33 These findings suggest that the
development of hypertriglyceridaemia may be related to absence
of peripheral fat depots (and possibly related to changes in their
adipokines), but also because of accumulation of ectopic
fat, allowing both mechanisms to be exploited for therapeutic
development.
As expected in patients with lipodystrophy, our patients had a
high prevalence of diabetes, often associated with extreme insu-
lin resistance. The incidence of diabetes was higher in our popu-
lation (826%), compared with that of a previously reported
cohort (50%).34 This discrepancy may be because of recruitment
of patients suspected to have NAFLD, and these patients may
have more severe metabolic co-morbidities. Microvascular com-
plications of diabetes, particularly peripheral neuropathy and
nephropathy were also common. Hypertriglyceridaemia and
NAFLD or NASH are known to have associations with lipodys-
trophy, and most of our patients also demonstrated this.2 Other
frequent conditions included recurrent pancreatitis, hyperten-
sion, PCOS, gastroesophagal reflux disease (GERD), sleep
apnoea and coronary artery disease or myocardial infarction.
Diabetes commonly co-exists with hypertension, hyperlipi-
daemia, kidney disease and cardiovascular disease.35 However,
we were surprised by the prevalence of chronic pain and mood
disorder in this group. Overall, chronic pain was present in
783% of patients and was reported to be because of a combina-
tion of arthritis, back pain, fibromyalgia and myopathy. Depres-
sion has been shown to be prevalent in adults with diabetes to a
varying degree (11–32%),36 but appears higher in our patients
(435%). It is not clear whether these under-appreciated mani-
festations are because of primary pathophysiological pathways, a
manifestation of ectopic lipid (or other metabolite) deposition
in muscles and nerves (or elsewhere) or because of some other
adaptive (neurobehavioural, possibly functional) processes.
We further explored the extent of liver disease and NASH by
histopathological criteria was present in nearly all patients (22 of
23). As our trial specifically sought patients with fatty liver dis-
ease at baseline, the presence of NASH may be overrepresenta-
tive of the prevalence of NASH in the entire population of PL.
It is noteworthy that significant fibrosis may be present even in
young patients without diabetes as was shown in a 12-year-old
female patient. Therefore, it would be important to consider a
liver biopsy or a careful investigation for clinical fibrosis even in
very young patients with PL.
Lastly, we present data that reflect relative nuclear integrity in
the liver tissue of PL. Lamin A and lamin C are integral compo-
nents of the nuclear envelope and are expressed ubiquitously
throughout the body. Alterations in the nuclear envelope may
lead to premature cell apoptosis. LMNA pathogenic variants
may increase the risk of arrhythmia or cardiomyopathy, as
occurred in two of our patients with non-ischaemic
cardiomyopathy (one requiring cardiac transplantation).37 Given
that patients had multi-system involvement, we examined the
degree of nuclear disorganization in liver biopsy tissues of select
patients. Patients with LMNA pathogenic variants had apparent
nuclear disorganization in their liver tissue. We also noted a
similar pattern, although not to the same degree, in a patient
harbouring a POLD1 variant of uncertain significance that is
likely pathogenic. We posit nuclear atypia and disorganization
may be a unifying cellular phenomenon in patients with PL
depending on the mutation and the involved gene. This phe-
nomenon may contribute to the multisystem involvement in PL.
Further work is warranted in this arena.
Overall, PL was associated with involvement of at least 10
organ systems (with manifestations present in all 10 in nearly
40% of patients). The involvement of multiple organs in PL
bears some resemblance to other heterogeneous rare metabolic
diseases such as glycogen storage disease. Researchers studying
Gaucher disease have developed a disease severity score tool,38
making use of the number of organ systems affected, severity of
signs and symptoms and functional limitations. The diversity of
comorbid conditions in our patients has inspired us to propose
adoption of a similar approach to define the disease burden
more objectively. If such a tool can be developed and validated,
the impact of disease modifying treatments can be better
measured.
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